GSK of­floads two vac­cines in $1.1B deal as it works to re­vive the pipeline

Glax­o­SmithK­line is leav­ing the deep dark woods and its virus­es be­hind.

GSK has agreed to di­vest its vac­cines for ra­bies, RabAvert, and tick-born en­cephali­tis vac­cine, En­cepur, to Bavar­i­an Nordic, part of the com­pa­ny’s broad­er ef­forts to nar­row its pipeline and fo­cus on on­col­o­gy and im­munol­o­gy.

The deal is worth up to near­ly $1.1 bil­lion, with a $336 mil­lion up­front pay­ment. GSK ac­quired the vac­cines from No­var­tis as part of an ex­change for their late-stage on­col­o­gy pro­grams in 2015 un­der for­mer chief Sir An­drew Wit­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.